You can bring us the product form, not only the material. Through our health-food OEM/ODM affiliate (TENMARU SEIYAKU Co., Ltd.), material selection, formulation design and manufacture run through one point of contact — including at the stage where only the claim is settled.
1. The dose decides the dosage form
The order is claim → component amount → material quantity → dosage form. Starting from the other end leads to a dead end.
| Scale of the daily dose | Typical materials | Forms that fit |
|---|---|---|
| μg to a few mg | Glucosylceramide (1.2 mg), vitamin D | Comfortably in a tablet or capsule |
| Tens of mg | Lutein 10 mg + zeaxanthin 2 mg | Tablet, softgel |
| Tens of mg | Bilberry-derived anthocyanins 43.2 mg | Tablet, capsule |
| Hundreds of mg to 1 g | GABA, collagen peptide (low end) | Tablet count rises; powder is easier |
| Several grams | Inulin 4.5 g, collagen peptide 2–5 g | Not realistic as a tablet. Powder, stick, beverage |
Inulin shows this plainly. The most common notified dose is 4.5 g, which will not fit in a tablet. The same dataset also holds a substantial number of 750 mg designs, which leave the form open. By the time the dose is set, the form is largely decided.
2. Material properties constrain the process
- Oil-soluble — carotenoids such as lutein and astaxanthin suit softgels or emulsified preparations; for tableting, choose a prepared form
- Hygroscopic — the free base of L-carnitine is hygroscopic, which affects tablet hardness and storage stability. Choosing a salt form can avoid it
- Particle size — tableting needs flow and fill behaviour; powder filling needs resistance to segregation. The same substance is often offered in several particle-size grades
- Heat resistance — spore-forming bacteria tolerate heat, which is precisely why they are designed in at 100 million cells. The design assumes that resistance, so changes to heat conditions call for a check
- Weighing precision — for materials dosed in small amounts, a premix reduces weighing error by an order of magnitude
3. Starting from trials and small lots
We take enquiries from trial and small-lot volumes. If scale-up is in view, settling these at the trial stage saves work later.
- Whether a single lot can cover the run, and continuity of specification across lots
- Lead time and minimum order quantity at scale
- The format required for specifications and COAs (share it in advance if the recipient is fixed)
- Regulatory confirmation — particularly for imported materials and the human/animal distinction
4. If a function claim is intended
Choose a material that can be identified as the functional ingredient from the selection stage. Substituting later is expensive.
- For bacteria, choose a material whose name carries the strain — a generic name cannot be designed on
- For extracts, fix the content basis first
- Set the target against live comparable notifications and their doses
- Confirm early that the dose and the intended form can coexist
See Regulatory Support for detail.
What to tell us
- The claim direction — the material may be undecided
- Target component amount — if set; otherwise we propose one
- Intended dosage form — if undecided, we work back from the dose
- Whether a function claim is in view — it changes material selection
- Expected quantity and schedule
Related: Business & Services / Catalog / Contact